TR200100134T2 - Bifenilsülfonil ihtiva eden imidazol türevleri,üretim yöntemi ve kullanımları. - Google Patents

Bifenilsülfonil ihtiva eden imidazol türevleri,üretim yöntemi ve kullanımları.

Info

Publication number
TR200100134T2
TR200100134T2 TR2001/00134T TR200100134T TR200100134T2 TR 200100134 T2 TR200100134 T2 TR 200100134T2 TR 2001/00134 T TR2001/00134 T TR 2001/00134T TR 200100134 T TR200100134 T TR 200100134T TR 200100134 T2 TR200100134 T2 TR 200100134T2
Authority
TR
Turkey
Prior art keywords
compounds
biphenylsulphonyl
production method
imidazole derivatives
derivatives containing
Prior art date
Application number
TR2001/00134T
Other languages
English (en)
Inventor
Kleemann Heinz-Werner
Lochen Lang Hans
Schwark Jan-Robert
Petry Stefan
Weichert Andreas
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of TR200100134T2 publication Critical patent/TR200100134T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formül (I)'e göre olan bilesikler olup, bu bilesiklerde semboller istemlerde belirtilen anlamlara sahiptir, bu bilesikler ayrica kardiyoprotektif komponentlere sahiptir. Sözkonusu bilesikler isemik kaynakli hasarlarin olusumunda, özellikle isemik kaynakli kalp aritmilerinin ortaya çikisindaki patofizyolojik ön olaylari preventif olarak önleyebilmekte veya güçlü sekilde azaltabilmektedir. Bunun yani sira bilesikler hücrelerin proliferasyonu üzerinde güçlü inhibe edici etkiye sahiptirler.
TR2001/00134T 1998-07-18 1999-07-10 Bifenilsülfonil ihtiva eden imidazol türevleri,üretim yöntemi ve kullanımları. TR200100134T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19832428A DE19832428A1 (de) 1998-07-18 1998-07-18 Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
TR200100134T2 true TR200100134T2 (tr) 2001-07-23

Family

ID=7874574

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00134T TR200100134T2 (tr) 1998-07-18 1999-07-10 Bifenilsülfonil ihtiva eden imidazol türevleri,üretim yöntemi ve kullanımları.

Country Status (18)

Country Link
US (1) US6369236B1 (tr)
EP (1) EP1097141B1 (tr)
JP (1) JP4567885B2 (tr)
KR (1) KR20010071957A (tr)
CN (1) CN1211370C (tr)
AR (1) AR019405A1 (tr)
AT (1) ATE362920T1 (tr)
AU (1) AU764438B2 (tr)
BR (1) BR9912241A (tr)
CA (1) CA2338059A1 (tr)
DE (2) DE19832428A1 (tr)
HU (1) HUP0102607A3 (tr)
ID (1) ID27774A (tr)
PL (1) PL345585A1 (tr)
RU (1) RU2246488C2 (tr)
TR (1) TR200100134T2 (tr)
WO (1) WO2000003996A1 (tr)
ZA (1) ZA200100278B (tr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19832429A1 (de) 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832428A1 (de) 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US20030220383A1 (en) * 2002-02-14 2003-11-27 Aventis Pharma Deutschland Gmbh Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders
DE10206354A1 (de) * 2002-02-14 2003-08-28 Aventis Pharma Gmbh Verwendung von Inhibitoren des Natrium-abhängigen Chlorid-Bicarbonat-Austauschers zur Behandlung von thrombotischen und inflammatorischer Erkrankungen
CA2691662A1 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag Imidazole derivatives as ccr2 receptor antagonists
JP5395905B2 (ja) 2008-09-02 2014-01-22 エルダー・ファーマシューティカルズ・リミテッド 抗炎症化合物
KR101044953B1 (ko) * 2009-01-07 2011-06-29 (주) 인우 코퍼레이션 이중분사노즐을 이용한 악취제거 시스템
WO2015198945A1 (ja) * 2014-06-23 2015-12-30 日産化学工業株式会社 スルホニル結合を有するシラン化合物の製造方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681067B1 (fr) * 1991-09-10 1993-12-17 Elf Sanofi Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
RU2104272C1 (ru) * 1991-01-04 1998-02-10 Хехст АГ Производные имидазола, способ их получения и фармацевтическая композиция, понижающая кровяное давление
CA2109524A1 (en) * 1991-05-10 1992-11-11 Prasun K. Chakravarty Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
TW215434B (tr) * 1992-03-07 1993-11-01 Hoechst Ag
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
FR2711367B1 (fr) * 1993-10-19 1995-12-01 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
FR2711368B1 (fr) * 1993-09-16 1996-01-05 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
FR2716882B1 (fr) 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0855392A3 (de) * 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832428A1 (de) 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
AR019405A1 (es) 2002-02-20
CN1309645A (zh) 2001-08-22
WO2000003996A1 (de) 2000-01-27
ZA200100278B (en) 2001-08-06
JP4567885B2 (ja) 2010-10-20
HUP0102607A2 (hu) 2002-03-28
HK1038743A1 (en) 2002-03-28
CA2338059A1 (en) 2000-01-27
EP1097141A1 (de) 2001-05-09
ATE362920T1 (de) 2007-06-15
DE19832428A1 (de) 2000-01-20
AU764438B2 (en) 2003-08-21
EP1097141B1 (de) 2007-05-23
JP2002520399A (ja) 2002-07-09
AU5280799A (en) 2000-02-07
BR9912241A (pt) 2001-04-10
PL345585A1 (en) 2001-12-17
CN1211370C (zh) 2005-07-20
KR20010071957A (ko) 2001-07-31
HUP0102607A3 (en) 2002-05-28
DE59914347D1 (de) 2007-07-05
US6369236B1 (en) 2002-04-09
RU2246488C2 (ru) 2005-02-20
ID27774A (id) 2001-04-26

Similar Documents

Publication Publication Date Title
TR199800084A2 (tr) Bifenilsülfonil ikameli bes üyeli heterosiklenler, bunlarin üretimi.
TWI263235B (en) Material for electrolytic solutions and use thereof
YU39101A (sh) Aromatična hetrerociklična jedinjenja kao antiinflamatorni agensi
AU1617901A (en) Urea derivatives as anti-inflammatory agents
TR199700844T1 (tr) Pirazolil-Benzoil Türevleri.
DE60023853D1 (de) Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
CA2059000A1 (en) Fused-ring aryl substituted imidazoles
WO1991019707A3 (en) Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
DE60024830T2 (de) Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
EP1138805A3 (en) Tin electolyte
CA2241787A1 (en) Substituted aza- and diazacycloheptane and cyclooctane compounds and their use
TR199700803T1 (tr) Trombin-inhibitörleri olarak yeni dipeptidik amidinler.
CA2297911A1 (en) Substituted 6-phenylphenanthridines
CA2359440A1 (en) Phenylphenanthridines with pde-iv inhibiting activity
CA2510945A1 (en) Intermediates useful in production of antivirally active heterocyclic azahexane derivatives
CA2270964A1 (en) Benzonaphthyridines as bronchial therapeutics
CA2082923A1 (en) Sulfonyl compounds
CA2177821A1 (en) Prolyl Endopeptidase Inhibitors
DE59408399D1 (de) Arylessigsäurederivate und ihre verwendung als fungizide
TR200002580T2 (tr) Hücre çoğalmasının engellenmesinde kullanılan ikameli bisindolimaleimitler
EP0635506A4 (en) CONNECTION WITH ANTIPSYCHOTIC EFFECT.
AU2668800A (en) Mixture of plant-treatment agents and waxes, method for producing same and the use thereof
TR200002255T2 (tr) Bifenilsülfonilsiyonamidler, üretim yöntemi ve ilaç olarak kullanımları.
CA2309474A1 (en) New 4-arylpiperidine derivatives for the treatment of pruritus
WO1999037291A3 (de) Verwendung von substituierten sulfonamiden als antivirale mittel und neue stoffe